obesity

News

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

News

Experts think the current way of defining obesity based on BMI isn't nuanced enough to gauge health and the need for weight-loss therapies.

R&D

The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.

News

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.

News

A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.

News

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.